simvastatin

simvastatin
IUPAC name	(1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate
Tradename	Zocor, others
Drugs.com	Monograph
MedlinePlus	a692030
Routes of administration	By mouth
Bioavailability	5%
Protein bound	95%
Metabolism	Liver (CYP3A4)
Elimination half-life	2 hours for simvastatin, 1.9 hours for simvastatin acid
Excretion	Feces (60%), urine (13%)
CAS number	79902-63-9
PubChem	54454
DrugBank	DB00641
ChemSpiderID	49191
UNII	AGG2FN16EV
ChEBI	9150
ChEMBL	942
ATC prefix	C10
ATC suffix	AA01
Legal AU	S4
Legal UK	POM
Legal US	Rx-only

simvastatin is a member of the statin class of medications, which are used to lower low-density lipoprotein (LDL) cholesterol and reduce the risk of cardiovascular disease. It is indicated for the primary and secondary prevention of major vascular events, such as myocardial infarction and stroke, in individuals at elevated risk. The drug functions by inhibiting the enzyme HMG-CoA reductase, a critical catalyst in the mevalonate pathway responsible for cholesterol synthesis within the liver.

Medical uses

Simvastatin is primarily prescribed for the management of hypercholesterolemia and dyslipidemia, aiming to reduce elevated levels of total cholesterol and LDL cholesterol. It is a cornerstone in both primary prevention strategies for patients with risk factors like diabetes mellitus and secondary prevention following events like an acute coronary syndrome. Landmark clinical trials such as the Scandinavian Simvastatin Survival Study (4S) and the Heart Protection Study demonstrated its efficacy in significantly decreasing mortality and morbidity from coronary artery disease. The medication is also used in certain inherited lipid disorders, such as heterozygous familial hypercholesterolemia, often in conjunction with dietary modifications.

Adverse effects

The most common adverse reactions associated with simvastatin are generally mild and include myalgia, headache, and gastrointestinal disturbances. A serious but rare class effect of statins is rhabdomyolysis, a severe muscle injury that can lead to acute kidney injury and is more likely at higher doses or with concomitant use of certain medications. Other potential risks involve hepatotoxicity, indicated by elevated liver function test results, and an increased incidence of type 2 diabetes mellitus noted in long-term studies. The U.S. Food and Drug Administration has issued warnings regarding the 80 mg dose due to its heightened myopathy risk.

Pharmacology

Simvastatin is a prodrug that is administered in its lactone form and undergoes hydrolysis in the liver to its active beta-hydroxyacid form. This active metabolite competitively inhibits HMG-CoA reductase, the rate-limiting enzyme in the mevalonate pathway, thereby depleting intracellular cholesterol pools. This depletion triggers an upregulation of LDL receptors on hepatocyte surfaces, increasing the clearance of LDL cholesterol from the bloodstream. Its pharmacokinetics are characterized by extensive first-pass metabolism, primarily by the cytochrome P450 system isoform CYP3A4, and high binding to plasma proteins.

Interactions

Concomitant administration with potent inhibitors of the CYP3A4 enzyme system significantly increases simvastatin exposure and the risk of myopathy. Such agents include certain antifungal drugs like itraconazole, antibiotics like clarithromycin, and protease inhibitors used in HIV therapy such as ritonavir. Concurrent use with gemfibrozil, cyclosporine, danazol, or amiodarone is also contraindicated or requires stringent dose limitations. Patients are advised to avoid consuming large quantities of grapefruit juice, which can inhibit CYP3A4 and potentiate drug effects.

History

Simvastatin was developed from a fermentation product of the fungus Aspergillus terreus, following the pioneering discovery of mevastatin by Akira Endo at the Sankyo company in Japan. It was first synthesized by researchers at Merck & Co., building upon the work of Carl Hoffman. The drug received approval from the U.S. Food and Drug Administration in 1991 under the brand name Zocor. Its profound impact was solidified by the publication of the landmark Scandinavian Simvastatin Survival Study in 1994, which provided definitive evidence of mortality benefit, revolutionizing the management of atherosclerotic cardiovascular disease.

Society and culture

Simvastatin was one of the world's best-selling medications for many years, with global sales for Zocor exceeding $5 billion annually before its patent expired. Its patent exclusivity in the United States ended in 2006, leading to the widespread availability of generic versions manufactured by companies like Teva Pharmaceutical Industries and Mylan. The drug is on the World Health Organization's List of Essential Medicines, underscoring its importance in public health. The cost-effectiveness of generic simvastatin has made it a fundamental tool in national health programs worldwide for combating the burden of cardiovascular disease.

Category:Drugs